US Bancorp
ATRA icon

US Bancorp’s Atara Biotherapeutics ATRA Stock Holding History

US Bancorp’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-71
Closed -$2.62K – 3982
2023
Q3 		$2.62K Hold
71
– – ﹤0.01% 3595
2023
Q2 		$2.85K Buy
71
+29
+69% +$1.64K ﹤0.01% 3616
2023
Q1 		$3.08K Sell
42
-92
-69% -$8.92K ﹤0.01% 3666
2022
Q4 		$11K Sell
134
-173
-56% -$18K ﹤0.01% 3264
2022
Q3 		$29K Buy
307
+302
+6,040% +$33.9K ﹤0.01% 2827
2022
Q2 		$1K Hold
5
– – ﹤0.01% 3927
2022
Q1 		$1K Sell
5
-3
-38% -$955 ﹤0.01% 3908
2021
Q4 		$3K Hold
8
– – ﹤0.01% 3770
2021
Q3 		$4K Hold
8
– – ﹤0.01% 3689
2021
Q2 		$3K Hold
8
– – ﹤0.01% 3710
2021
Q1 		$3K Hold
8
– – ﹤0.01% 3591
2020
Q4 		$4K Sell
8
-3
-27% -$1.39K ﹤0.01% 3431
2020
Q3 		$4K Buy
11
+3
+38% +$1.02K ﹤0.01% 3336
2020
Q2 		$3K Sell
8
-1
-11% -$253 ﹤0.01% 3418
2020
Q1 		$2K Sell
9
-4
-31% -$1.27K ﹤0.01% 3433
2019
Q4 		$5K Sell
13
-1
-7% -$345 ﹤0.01% 3263
2019
Q3 		$5K Buy
+14
New +$5.22K ﹤0.01% 3226

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's ATRA Position: Q4 2023 in Review

US Bancorp sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 71 shares — an estimated $2.62K sold.

US Bancorp first reported a position in ATRA in Q3 2019 and held it in 17 quarters. The position peaked at $29K in Q3 2022. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • US Bancorp reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • US Bancorp sold 71 Atara Biotherapeutics shares in Q4 2023, an estimated $2.62K.
  • US Bancorp first reported a position in Atara Biotherapeutics in Q3 2019 and held it in 17 quarters.
  • US Bancorp's Atara Biotherapeutics position peaked at $29K in Q3 2022.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on US Bancorp's 13F filing for Q4 2023, filed 9 Feb 2024.